Patents by Inventor John Simard

John Simard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnosis, treatment, and prevention of vascular disorders using interleukin-1 autoantibodies
    Publication number: 20120231012
    Abstract: Method of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1? autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1? autantibodies.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 13, 2012
    Applicant: XBIOTECH, INC.
    Inventors: John Simard, Klaus Bendtzen
  • Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
    Patent number: 8242074
    Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: August 14, 2012
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120164665
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: June 28, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies
    Patent number: 8187817
    Abstract: Methods of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1? autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1? autoantibodies.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: May 29, 2012
    Assignee: XBiotech, Inc.
    Inventors: John Simard, Klaus Bendtzen
  • IL-1alpha immunization induces autoantibodies protective against atherosclerosis
    Publication number: 20120114598
    Abstract: Immunization of a mammal with IL-1?, which causes the mammal to generate IL-1? autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment.
    Type: Application
    Filed: January 9, 2012
    Publication date: May 10, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Methods for identifying a subject who has developed an anti-antibody response
    Publication number: 20120094395
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: December 2, 2011
    Publication date: April 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Characterizing an allotypic phenotype of a subject
    Publication number: 20120094301
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: December 2, 2011
    Publication date: April 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Treatment for Neoplastic Diseases
    Publication number: 20120045444
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Application
    Filed: August 23, 2011
    Publication date: February 23, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John SIMARD
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120021512
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 26, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120014971
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120015384
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120015433
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Arthritis Treatment
    Publication number: 20110311547
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 22, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1? antibodies
    Patent number: 8034337
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: October 11, 2011
    Assignee: Xbiotech, Inc.
    Inventor: John Simard
  • Method of modifying a monoclonal antibody
    Publication number: 20110071276
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Panel of monoclonal antibody containing pharmaceutical compositions
    Publication number: 20110071054
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Method and devices for identifying and treating a subject who has developed an anti-antibody response
    Publication number: 20110070230
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Method of selecting a monoclonal antibody for administration
    Publication number: 20110070229
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • IL-1alpha immunization induces autoantibodies protective against atherosclerosis
    Publication number: 20110008282
    Abstract: Immunization of a mammal with IL-1?, which causes the mammal to generate IL-1? autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment.
    Type: Application
    Filed: September 22, 2010
    Publication date: January 13, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Targeting pathogenic monocytes
    Publication number: 20100068212
    Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.
    Type: Application
    Filed: September 14, 2009
    Publication date: March 18, 2010
    Applicant: XBiotech, Inc.
    Inventor: John Simard